Elzanor (12.5/1000mg) 14 Tablets
Empagliflozin and metformin 12.5/1000mg for type 2 diabetes.
Elzanor (12.5/1000mg) combines empagliflozin (SGLT2 inhibitor) and metformin for type 2 diabetes. Empagliflozin increases urinary glucose excretion; metformin reduces hepatic glucose output. Used when dual therapy is needed for glycaemic control and may offer cardiovascular benefit in indicated patients.
Purpose
Treatment of type 2 diabetes mellitus as adjunct to diet and exercise when dual therapy is appropriate.
Ingredients
Empagliflozin 12.5mg and metformin hydrochloride 1000mg per tablet.
Warnings
Contraindicated in severe renal impairment and diabetic ketoacidosis. Not for type 1 diabetes. Risk of genital and urinary infections.
Side Effects
Nausea, diarrhoea, urinary tract infections, genital mycotic infections, volume depletion. Rare: ketoacidosis. Report unusual tiredness or abdominal pain.
Storage Instructions
Store below 30°C in a dry place. Keep in original pack; protect from moisture.
| Brand | Tabros |
| Status | Active |
Related Products
